Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease

Journal of the American Society of Nephrology

Volumn 25, Issue 12, 2014, Pages 2800-2811

  Hanatani, Shinsuke ^a   Izumiya, Yasuhiro ^a   Araki, Satoshi ^a   Rokutanda, Taku ^a   Kimura, Yuichi ^a   Walsh, Kenneth ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; DOXYCYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; PROTEIN KINASE B; ADIPONECTIN; AKT1 PROTEIN, MOUSE; CYTOKINE; FBXO32 PROTEIN, MOUSE; MUSCLE PROTEIN; NITRIC OXIDE SYNTHASE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GENE; GENE EXPRESSION PROFILING; GENE REPRESSION; INFLAMMATION; INTRACELLULAR ADHESION MOLECULE 1 GENE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE GROWTH; NONHUMAN; OBSTRUCTION-INDUCED RENAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SKELETAL MUSCLE; TRANSGENIC MOUSE; UPREGULATION; URETER OBSTRUCTION; VASCULAR ADHESION MOLECULE 1 GENE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; CYTOLOGY; DISEASE MODEL; FIBROSIS; GLYCOLYSIS; KIDNEY; KIDNEY FAILURE; METABOLISM; MUSCLE; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPONECTIN; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; GLYCOLYSIS; INFLAMMATION; KIDNEY; MICE; MICE, TRANSGENIC; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCLES; MUSCULAR ATROPHY; MYOFIBROBLASTS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHYSICAL CONDITIONING, ANIMAL; PROTO-ONCOGENE PROTEINS C-AKT; RENAL INSUFFICIENCY; SKP CULLIN F-BOX PROTEIN LIGASES;

EID: 84919753380     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013091025     Document Type: Article

References (51)

1. Workeneh BT, Mitch WE: Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr 91: 1128S-1132S, 2010
2. Garibotto G, Bonanni A, Verzola D: Effect of kidney failure and hemodialysis on protein and amino acid metabolism. Curr Opin Clin Nutr Metab Care 15: 78-84, 2012
3. Kosmadakis GC, Bevington A, Smith AC, Clapp EL, Viana JL, Bishop NC, Feehally J: Physical exercise inpatientswith severe kidney disease. Nephron Clin Pract 115: c7-c16, 2010
4. Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O, Tourkantonis A, Deligiannis A: The effects of exercise training on muscle atrophy in haemodialysis patients. Nephrol Dial Transplant 13: 685-699, 1998
5. Anderson JE, Boivin MR Jr, Hatchett L: Effect of exercise training on interdialytic ambulatory and treatment-related blood pressure in hemodialysis patients. Ren Fail 26: 539-544, 2004
6. Kouidi E, Iacovides A, Iordanidis P, Vassiliou S, Deligiannis A, Ierodiakonou C, Tourkantonis A: Exercise renal rehabilitation program: Psychosocial effects. Nephron 77: 152-158, 1997
7. Howden EJ, Fassett RG, Isbel NM, Coombes JS: Exercise training in chronic kidney disease patients. Sports Med 42: 473-488, 2012
8. Kosmadakis GC, John SG, Clapp EL, Viana JL, Smith AC, Bishop NC, Bevington A, Owen PJ, McIntyre CW, Feehally J: Benefi ts of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant 27: 997-1004, 2012
9. Mustata S, Groeneveld S, Davidson W, Ford G, Kiland K, Manns B: Effects of exercise training on physical impairment, arterial stiffness and health-related quality of life in patients with chronic kidney disease: A pilot study. Int Urol Nephrol 43: 1133-1141, 2011
10. Balakrishnan VS, Rao M, Menon V, Gordon PL, Pilichowska M, Castaneda F, Castaneda-Sceppa C: Resistance training increases muscle mitochondrial biogenesis in patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 996-1002, 2010
11. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS: Resistance training to reduce the malnutrition-in flammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43: 607-616, 2004
12. Castaneda C, Gordon PL, Uhlin KL, Levey AS, Kehayias JJ, Dwyer JT, Fielding RA, Roubenoff R, Singh MF: Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 135: 965-976, 2001
13. Smart N, Steele M: Exercise training in haemodialysis patients: A systematic review and meta-analysis. Nephrology (Carlton) 16: 626-632, 2011
14. Datta SR, Brunet A, Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13: 2905-2927, 1999
15. Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H: Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. FASEB J 19: 786-788, 2005
16. Xu J, Li R, Workeneh B, Dong Y, Wang X, Hu Z: Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int 82: 401-411, 2012
17. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA, Ouchi N, LeBrasseur NK, Walsh K: Fast/glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 7: 159-172, 2008
18. Araki S, Izumiya Y, Hanatani S, Rokutanda T, Usuku H, Akasaki Y, Takeo T, Nakagata N, Walsh K, Ogawa H: Akt1-mediated skeletal muscle growth attenuates cardiac dysfunction and remodeling after experimental myocardial infarction. Circ Heart Fail 5: 116-125, 2012
19. Fujita M, Ye Q, Ouchi H, Harada E, Inoshima I, Kuwano K, Nakanishi Y: Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice. Antimicrob Agents Chemother 50: 739-743, 2006
20. Meran S, Steadman R: Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 92: 158-167, 2011
21. Bengatta S, Arnould C, Letavernier E, Monge M, de Préneuf HM, Werb Z, Ronco P, Lelongt B: MMP9 and SCF protect from apoptosis in acute kidney injury. J Am Soc Nephrol 20: 787-797, 2009
22. Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25: 1653-1663, 2011
23. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE: IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 20: 604-612, 2009
24. Niedermeier M, Reich B, Rodriguez Gomez M, Denzel A, Schmidbauer K, Göbel N, Talke Y, Schweda F, Mack M: CD4+ T cells control the differentiation of Gr1+monocytes into fibrocytes. Proc Natl Acad Sci U S A 106: 17892-17897, 2009
25. Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, Cruz PE, Roncal CA, Glushakova OY, Chiodo VA, Atkinson MA, Hauswirth WW, Flotte TR, Rodriguez-Iturbe B, Johnson RJ: IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol 16: 3651-3660, 2005
26. Yang J, Lin SC, Chen G, He L, Hu Z, Chan L, Trial J, Entman ML, Wang Y: Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol 24: 1644-1659, 2013
27. Ito D, Ito O, Mori N, Cao P, Suda C, Muroya Y, Hao K, Shimokawa H, Kohzuki M: Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure. Clin Exp Pharmacol Physiol 40: 617-625, 2013
28. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidneymodel. Am J Pathol 161: 239-248, 2002
29. Sun D, Wang Y, Liu C, Zhou X, Li X, Xiao A: Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction. Life Sci 90: 900-909, 2012
30. Ishikawa Y, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, Murakoshi M, Hagiwara S, Horikoshi S, Funabiki K, Tomino Y: Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res 2012: 702948, 2012
31. Ghosh S, Khazaei M, Moien-Afshari F, Ang LS, Granville DJ, Verchere CB, Dunn SR, McCue P, Mizisin A, Sharma K, Laher I: Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/dbmice. Am J Physiol Renal Physiol 296: F700-F708, 2009
32. Luiz RS, Silva KA, Rampaso RR, Antônio EL, Montemor J, Bocalini DS, Dos Santos L, Moura L, Tucci PJ, de Abreu NP, Schor N: Exercise attenuates renal dysfunction with preservation of myocardial function in chronic kidney disease. PLoS ONE 8: e55363, 2013
33. Silva KA, Luiz RS, Rampaso RR, de Abreu NP, Moreira ED, Mostarda CT, De Angelis K, de Paulo Castro Teixeira V, Irigoyen MC, Schor N: Previous exercise training has a beneficial effect on renal and cardiovascular function in a model of diabetes. PLoS ONE 7: e48826, 2012
34. Wang XH, Du J, Klein JD, Bailey JL, Mitch WE: Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int 76: 751-759, 2009
35. Verzola D, Procopio V, Sofia A, Villaggio B, Tarroni A, Bonanni A, Mannucci I, De Cian F, Gianetta E, Saffioti S, Garibotto G: Apoptosis andmyostatin mRNA are upregulated in the skeletalmuscle of patients with chronic kidney disease. Kidney Int 79: 773-782, 2011
36. Zhang L, Wang XH, Wang H, Du J, Mitch WE: Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 21: 419-427, 2010
37. Kuan Y, Surman J, Frystyk J, El Nahas AM, Flyvbjerg A, Haylor JL: Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease. Growth HormIGF Res 19: 219-225, 2009
38. Teppala S, Shankar A, Sabanayagam C: Association between IGF-1 and chronic kidney disease among US adults. Clin Exp Nephrol 14: 440-444, 2010
39. Chen Y, Sood S, McIntire K, Roth R, Rabkin R: Leucine-stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats. Am J Physiol Endocrinol Metab 301: E873-E881, 2011
40. Akasaki Y, Ouchi N, Izumiya Y, Bernardo BL, Lebrasseur NK, Walsh K: Glycolytic fast-twitch muscle fiber restoration counters adverse age-related changes in body composition and metabolism. Aging Cell 13: 80-91, 2014
41. Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-F9, 2008
42. Chen KC, Hsieh CL, Peng CC, Peng RY: Exercise rescued chronic kidney disease by attenuating cardiac hypertrophy through the cardiotrophin-1 → LIFR/gp 130 → JAK/STAT3 pathway. Eur J Prev Cardiol 21: 507-520, 2012
43. Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, Walsh K: Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283: 32802-32811, 2008
44. Zemse SM, Chiao CW, Hilgers RH, Webb RC: Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta. Am J Physiol Heart Circ Physiol 299: H1160-H1167, 2010
45. Liu AC, Lee M, McManus BM, Choy JC: Induction of endothelial nitric oxide synthase expression by IL-17 in human vascular endothelial cells: Implications for vascular remodeling in transplant vasculopathy. J Immunol 188: 1544-1550, 2012
46. Thomas SS, Mitch WE: Mechanisms stimulating muscle wasting in chronic kidney disease: The roles of the ubiquitin-proteasome system and myostatin. Clin Exp Nephrol 17: 174-182, 2013
47. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004
48. Grill MA, Bales MA, Fought AN, Rosburg KC, Munger SJ, Antin PB: Tetracycline-inducible system for regulation of skeletal muscle-specific gene expression in transgenic mice. Transgenic Res 12: 33-43, 2003
49. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K: Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005
50. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S, Leemans JC: TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 21: 1299-1308, 2010
51. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R: Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension 59: 308-316, 2012